TY - JOUR
T1 - Prognostic factors and survival in Ewing’s sarcoma treated by limb salvage surgery
AU - Trullols-Tarrago, L.
AU - Alvarez-SanNicolas, J.
AU - Lamas-Gomez, C.
AU - Peiro-Ibañez, A.
AU - Gracia-Alegria, I.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - © 2019, Federación de Sociedades Españolas de Oncología (FESEO). Purpose: Survival in Ewing’s sarcoma (ES) has increased with the use of chemotherapy. Surgical techniques such as limb salvage (LS) have been developed. Survival and adverse events have been widely studied in general series of ES, but there are few specific series of ES cases treated by LS, despite this being the most commonly used (surgical) approach. The aim of this study was to determine survival and prognostic factors in ES patients undergoing LS. Patients and methods: We analysed all ES patients treated between January 1984 and May 2008 and selected all those treated by systemic multimodal therapy and LS. We assessed the influence of patient characteristics, tumour parameters and therapeutic results in event-free survival (EFS). Results: Ninety patients were included. Fifty of them were treated by systemic multimodal therapy and locally by LS. ean age was 20 years. Overall survival (OS) was 68.8% and EFS was 60.6% at years. In the univariate analysis, pelvic location, age and response to chemotherapy were associated with poor prognosis. After multivariate analysis, poor response to treatment, pelvis location and age between 12 and 17 years were found to be independent prognostic factors. Dissemination at diagnosis was not a prognostic factor. Conclusions: OS and EFS in ES treated by LS were similar to findings in previous ES studies. factors are no different, except for the presence of metastasis at diagnosis.
AB - © 2019, Federación de Sociedades Españolas de Oncología (FESEO). Purpose: Survival in Ewing’s sarcoma (ES) has increased with the use of chemotherapy. Surgical techniques such as limb salvage (LS) have been developed. Survival and adverse events have been widely studied in general series of ES, but there are few specific series of ES cases treated by LS, despite this being the most commonly used (surgical) approach. The aim of this study was to determine survival and prognostic factors in ES patients undergoing LS. Patients and methods: We analysed all ES patients treated between January 1984 and May 2008 and selected all those treated by systemic multimodal therapy and LS. We assessed the influence of patient characteristics, tumour parameters and therapeutic results in event-free survival (EFS). Results: Ninety patients were included. Fifty of them were treated by systemic multimodal therapy and locally by LS. ean age was 20 years. Overall survival (OS) was 68.8% and EFS was 60.6% at years. In the univariate analysis, pelvic location, age and response to chemotherapy were associated with poor prognosis. After multivariate analysis, poor response to treatment, pelvis location and age between 12 and 17 years were found to be independent prognostic factors. Dissemination at diagnosis was not a prognostic factor. Conclusions: OS and EFS in ES treated by LS were similar to findings in previous ES studies. factors are no different, except for the presence of metastasis at diagnosis.
KW - Ewing’s sarcoma
KW - Prognosis
KW - Humans
KW - Middle Aged
KW - Kaplan-Meier Estimate
KW - Neoplasm Recurrence, Local
KW - Male
KW - Limb reconstruction
KW - Young Adult
KW - Ewing
KW - Analysis of Variance
KW - Progression-Free Survival
KW - Adolescent
KW - Bone sarcoma
KW - Adult
KW - Female
KW - Limb salvage
KW - Retrospective Studies
KW - Sarcoma, Ewing/drug therapy
KW - Limb Salvage/adverse effects
KW - Bone Neoplasms/drug therapy
UR - http://www.mendeley.com/research/prognostic-factors-survival-ewings-sarcoma-treated-limb-salvage-surgery
UR - https://dialnet.unirioja.es/servlet/articulo?codigo=7059036
U2 - 10.1007/s12094-019-02067-1
DO - 10.1007/s12094-019-02067-1
M3 - Article
C2 - 30798513
SN - 1699-048X
VL - 21
SP - 1374
EP - 1382
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
ER -